PepGen Shares Surge Following Positive Mid-Stage Trial Data for Myotonic Dystrophy Therapy
PepGen (PEPG) experienced a significant premarket surge of nearly 100% following the release of updated clinical data from its mid-stage trial. The study evaluates PGN-EDODM1, the company's lead therapeutic candidate designed to treat myotonic dystrophy type 1, a rare genetic disorder that impacts muscle function and multiple bodily systems. The positive readout regarding the asset's performance has driven intense investor interest, reflecting optimism around the potential commercial viability of the therapy. As a mid-stage trial update, these results represent a critical milestone in the development pipeline for PepGen's neuromuscular program.
Tickers: $PEPG